Stage and tissue-specific prognostic impact of miR-182 in NSCLC

BMC Cancer

Roy M Bremnes¹  Lill-Tove Busund²  Samer Al-Saad²  Sigve Andersen¹  Tom Donnem¹  Helge Stenvold¹ 

[1]Department of Oncology, University Hospital of North Norway, Tromso 9038, Norway

[2]Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway

关键词: miRNA;    miR-182;    Prognostic impact;    Survival;    Stage I-IIIA;    NSCLC;   

Others  :  859018
DOI  :  10.1186/1471-2407-14-138

 received in 2013-04-25, accepted in 2014-02-12,  发布年份 2014

【 摘 要 】

Background

MicroRNA (miR)-182 is frequently upregulated in cancers, has generally been viewed as an oncogene and is possibly connected to angiogenesis. We aimed to explore what impact miR-182 has in non-small cell lung cancer (NSCLC), and more explicitly its correlation with angiogenic markers.

Methods

From 335 unselected stage I to IIIA NSCLC carcinomas, duplicate tumor and tumor-associated stromal cores were collected in tissue microarray blocks (TMAs). In situ hybridization (ISH) was used to detect the expression of miR-182 in tumor cells, and immunohistochemistry (IHC) was used to detect the expression of angiogenesis related protein markers.

Results

In univariate analyses, high tumor cell expression of miR-182 was a positive prognostic factor for patients with squamous cell carcinoma (SCC, P = 0.042) and stage II patients (P = 0.003). Also in the multivariate analysis, high tumor cell miR-182 expression was associated with a good prognosis in the same groups (SCC: HR 0.57, CI 95% 0.33-0.99, P = 0.048; stage II: HR 0.50, CI 95% 0.28-0.90, P = 0.020). We found significant correlations between miR-182 and the angiogenesis related markers FGF2, HIF2α and MMP-7.

Conclusion

In patients with SCC and in stage II patients, high tumor cell miR-182 expression is an independent positive prognostic factor.

【 授权许可】

   
2014 Stenvold et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
• [2]Drilon A, Rekhtman N, Ladanyi M, Paik P: Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012, 13:e418-e426.
• [3]Ma PC: Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med 2012, 79(Electronic Suppl 1):eS56-eS60.
• [4]Kasinski AL, Slack FJ: Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011, 11:849-864.
• [5]Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
• [6]Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
• [7]Cho WC, Chow AS, Au JS: Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 2009, 45:2197-2206.
• [8]Guan P, Yin Z, Li X, Wu W, Zhou B: Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res 2012, 31:54. BioMed Central Full Text
• [9]Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J: A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011, 17:6802-6811.
• [10]Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, Wang MX: Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011, 4:575-586.
• [11]Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang YK: Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer 2011, 11:393. BioMed Central Full Text
• [12]Jiang L, Mao P, Song L, Wu J, Huang J, Lin C, Yuan J, Qu L, Cheng SY, Li J: miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol 2010, 177:29-38.
• [13]Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, Polsky D, Wei J, Lee P, Belitskaya-Levy I, Bhardwaj N, Osman I, Hernando E: Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 2009, 106:1814-1819.
• [14]Poell JB, van Haastert RJ, de Gunst T, Schultz IJ, Gommans WM, Verheul M, Cerisoli F, van Noort PI, Prevost GP, Schaapveld RQ, Cuppen E: A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability. PLoS One 2012, 7:e43569.
• [15]Sun Y, Fang R, Li C, Li L, Li F, Ye X, Chen H: Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun 2010, 396:501-507.
• [16]Yan D, Dong XD, Chen X, Yao S, Wang L, Wang J, Wang C, Hu DN, Qu J, Tu L: Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One 2012, 7:e40967.
• [17]Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, Andersen S, Stenvold H, Al-Shibli K, Al-Saad S, Bremnes RM, Busund LT: MicroRNA signatures in tumor tissue related to angiogenesis in Non-small cell lung cancer. PLoS One 2012, 7:e29671.
• [18]Rami-Porta R, Chansky K, Goldstraw P: Updated lung cancer staging system. Future Oncol 2009, 5:1545-1553.
• [19]Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT, Bremnes RM: Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007, 13:6649-6657.
• [20]Jorgensen S, Baker A, Moller S, Nielsen BS: Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 2010, 52:375-381.
• [21]Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM: Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer 2011, 72:294-302.
• [22]Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM: Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009, 4:578-585.
• [23]Stenvold H, Donnem T, Andersen S, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM: Overexpression of matrix metalloproteinase-7 and −9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome. Lung Cancer 2012, 75:235-241.
• [24]Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepeniuk M, Cohen L, Dan H, Zion O, Strenov Y, Polak-Charcon S, Perelman M: MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract 2010, 206:578-584.
• [25]Barshack I, Meiri E, Rosenwald S, Lebanony D, Bronfeld M, Aviel-Ronen S, Rosenblatt K, Polak-Charcon S, Leizerman I, Ezagouri M, Zepeniuk M, Shabes N, Cohen L, Tabak S, Cohen D, Bentwich Z, Rosenfeld N: Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Biol 2010, 42:1355-1362.
• [26]Lin PY, Yu SL, Yang PC: MicroRNA in lung cancer. Br J Cancer 2010, 103:1144-1148.
• [27]Donnem T, Eklo K, Berg T, Sorbye SW, Lonvik K, Al-Saad S, Al-Shibli K, Andersen S, Stenvold H, Bremnes RM, Busund LT: Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med 2011, 9:6. BioMed Central Full Text
• [28]Huynh C, Segura MF, Gaziel-Sovran A, Menendez S, Darvishian F, Chiriboga L, Levin B, Meruelo D, Osman I, Zavadil J, Marcusson EG, Hernando E: Efficient in vivo microRNA targeting of liver metastasis. Oncogene 2011, 30:1481-1488.
• [29]Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, Gorospe M, Harris AL, Helleday T, Chowdhury D: miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011, 41:210-220.
• [30]Tang T, Wong HK, Gu W, Yu MY, To KF, Wang CC, Wong YF, Cheung TH, Chung TK, Choy KW: MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol 2013, 129:199-208.
• [31]Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X, Tang H: MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. FEBS J 2012, 279:1252-1260.
• [32]Zhang L, Liu T, Huang Y, Liu J: microRNA-182 inhibits the proliferation and invasion of human lung adenocarcinoma cells through its effect on human cortical actin-associated protein. Int J Mol Med 2011, 28:381-388.
• [33]Zhou W, Feng X, Wu Y, Benge J, Zhang Z, Chen Z: FGF-receptor substrate 2 functions as a molecular sensor integrating external regulatory signals into the FGF pathway. Cell Res 2009, 19:1165-1177.
• [34]Ding K, Lopez-Burks M, Sanchez-Duran JA, Korc M, Lander AD: Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol 2005, 171:729-738.
• [35]Holnthoner W, Kerenyi M, Groger M, Kratochvill F, Petzelbauer P: Regulation of matrilysin expression in endothelium by fibroblast growth factor-2. Biochem Biophys Res Commun 2006, 342:725-733.